首页 | 本学科首页   官方微博 | 高级检索  
     


Eosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the disease
Authors:Alvise Berti  Sara Boukhlal  Matthieu Groh  Divi Cornec
Affiliation:1. Department of Rheumatology, Santa Chiara Hospital, Trento, Italy;2. Department of Cellular, Computational and Integrative Biology-CIBIO, University of Trento, Trento, Italyalvise.berti@apss.tn.it"ORCIDhttps://orcid.org/0000-0002-7831-921X;4. INSERM UMR1227, Lymphocytes B et Autoimmunité, Université de Bretagne Occidentale, CHU de Brest, Brest, France;5. Department of Internal Medicine, H?pital Foch, National Referral Center for Hypereosinophilic Syndrome (CEREO), Suresnes, France
Abstract:
ABSTRACT

Introduction: Eosinophilic granulomatosis with polyangiitis (EGPA) usually occurs in patients with late-onset asthma and sustained peripheral blood eosinophilia and classically presents with a clinical multifaceted spectrum of manifestations, which may vary at the different stages of the natural history of the disease.

Areas covered: We reviewed EGPA clinical presentation, focusing on clinical manifestations at three different phases of the disease: 1/before the development of overt vasculitis, 2/at vasculitis diagnosis and 3/during the long-term follow-up. An update on current classification criteria and recent therapeutic advances has been provided as well.

Expert opinion: Asthma, chronic rhinosinusitis and blood eosinophilia could anticipate the overt vasculitis for years. An atopic background may be present in a subset of patients (25-30%), while ANCA presence varies between 10 and 40%. Systemic vasculitis rapidly occurs and clinical features demonstrating vasculitis processes (neuropathy, purpura, scleritis, alveolar hemorrhage and glomerulonephritis) develop along with systemic symptoms (50%). After vasculitis resolution, asthma remains severe in up to 50% of patients and incidence of isolated-asthma and rhinosinus exacerbations remains constantly high. Different sets of classification criteria have been published so far, and DCVAS diagnostic criteria will be presented soon. Interleukin-5 blockers seem to be promising to control the disease and to spare corticosteroids.
Keywords:Severe/uncontrolled asthma  eosinophilic asthma  eosinophilic granulomatosis with polyangiitis  EGPA  Churg-Strauss  ANCA-associated vasculitis  long-term outcomes  vasculitis  mepolizumab  Interleukin-5
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号